IMDX (Insight Molecular Diagnostics) Selling, General, & Admin. Expense: $17.04 Mil (TTM As of Mar. 2026)


IMDX Insight Molecular Diagnostics Inc IMDX
49 GF Score
Price $4.70
GF Value $1.25
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Insight Molecular Diagnostics Selling, General, & Admin. Expense?

Insight Molecular Diagnostics IMDX -4.67% 49 Selling, General, & Admin. Expense is $17.04 Mil as of Mar. 2026. GuruFocus rates IMDX with a GF Score™ of 49/100 and a GF Value™ of $1.25 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Insight Molecular Diagnostics's selling, general, & admin. expense for the three months ended in Mar. 2026 was $5.14 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2026 was $17.04 Mil.


Insight Molecular Diagnostics  (NAS:IMDX) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Insight Molecular Diagnostics Selling, General, & Admin. Expense Related Terms


Insight Molecular Diagnostics Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Insight Molecular Diagnostics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insight Molecular Diagnostics Selling, General, & Admin. Expense Chart

Insight Molecular Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.39 21.53 13.29 13.79 16.11

Insight Molecular Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.14 3.83 3.70 4.38 5.14

IMDX vs XGN, BDSX, BNR: Selling, General, & Admin. Expense Comparison

For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insight Molecular Diagnostics Selling, General, & Admin. Expense vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Insight Molecular Diagnostics's Selling, General, & Admin. Expense falls into.


IMDX
49GF Score
Insight Molecular Diagnostics Inc IMDX
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insight Molecular Diagnostics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of $17.04 Mil mean?
Insight Molecular Diagnostics (IMDX) has a Selling, General, & Admin. Expense of $17.04 Mil as of Mar. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Insight Molecular Diagnostics and its competitors.
Is Insight Molecular Diagnostics' Selling, General, & Admin. Expense too high?
Insight Molecular Diagnostics' current Selling, General, & Admin. Expense is $17.04 Mil. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' Selling, General, & Admin. Expense compare to XGN and BDSX?
Insight Molecular Diagnostics' Selling, General, & Admin. Expense of $17.04 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Medical Diagnostics & Research company?
A good Selling, General, & Admin. Expense depends on the Medical Diagnostics & Research industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Insight Molecular Diagnostics and its competitors. Insight Molecular Diagnostics's current Selling, General, & Admin. Expense is $17.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.25, compared to a current price of $4.70 — trading 276% above its estimated fair value. The current Selling, General, & Admin. Expense is $17.04 Mil. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current Selling, General, & Admin. Expense is $17.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?

Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued. The current stock price of $4.70 is trading 276% above its estimated GF Value™ of $1.25. GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.

Key valuation signals for IMDX:

  • Selling, General, & Admin. Expense: $17.04 Mil
  • GF Value™: $1.25 vs. price of $4.70 (276% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Insight Molecular Diagnostics Business Description

Other Exchanges 0KCC:UK7OC0:Germany
Address 2 International Plaza Drive, Suite 510, Nashville, TN, USA, 37217
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score

Get the complete analysis for IMDX

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.70
Price
$1.25
GF Value